Navigation Links
CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009

BRANFORD, Conn., Jan. 29 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), today reported its financial results for the fourth quarter and calendar year of 2008 and provided milestone and financial guidance for the first half of 2009.

During the three month period ended December 31, 2008, CuraGen utilized $3.8 million of cash and investments and ended the fourth quarter with $88 million of cash and investments. At December 31, 2008, CuraGen has outstanding $19 million of 4% convertible subordinated notes due February 2011 with a market value of approximately $15 million. For the quarter ended December 31, 2008, CuraGen reported total operating expenses of $4.1 million, compared to total operating expenses of $11.1 million during the same period in 2007. Included in fourth quarter operating expenses is approximately $0.5 million of restructuring charges for a reduction in work force undertaken in December 2008.

"We currently have $88 million of cash and investments on hand and an attractive Phase II development asset that shows activity in metastatic melanoma and promise in breast cancer." commented Dr. Timothy M. Shannon, President and Chief Executive Officer. "We are encouraged by the activity CR011-vcMMAE has demonstrated to date and we will be releasing additional data on our two ongoing trials in the second quarter of 2009" commented Dr. Shannon.

2009 Milestones and Financial Guidance

The following statements are based on CuraGen's current expectations. These statements are forward-looking and actual results may differ materially. Please see the note regarding Forward-Looking Statements in this release for a description of certain important risk factors that could cause actual results to differ and refer to CuraGen's periodic reports on file with the Securities and Exchange Commission for a more complete description of the risks.

Anticipated milestones for CR011-vcMMAE through June 2009 include:

  • Complete and report on the final Phase II results of CR011-vcMMAE in metastatic melanoma in the second quarter of 2009

  • Advance and report on the initial Phase II results of CR011-vcMMAE in breast cancer in the second quarter of 2009

CuraGen expects to use an average of $3.5 to $4.0 million of cash and investments per quarter in the first half of 2009 to fund operations and also expects to end the second quarter of 2009 with between $80 and $81 million of cash and investments.

Forward-Looking Statements

Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, including statements relating to the Company's revenue, expenses, depreciation, amortization, asset impairment charges, losses, income, and future cash and investment positions, the timing and expected results of our clinical programs, and the development and marketability of planned drugs, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including the risk that any one or more of CuraGen's drug development programs will not proceed as planned for technical, scientific or commercial reasons or due to patient enrollment issues or based on new information from nonclinical or clinical studies or from other sources, the success of competing products and technologies, CuraGen's stage of development as a biopharmaceutical company, government regulation and healthcare reform, technological uncertainty and product development risks, product liability exposure, uncertainty of additional funding, CuraGen's history of incurring losses and the uncertainty of achieving profitability, reliance on research collaborations and strategic alliances, competition, patent infringement claims against CuraGen's products, processes and technologies, CuraGen's ability to protect its patents and proprietary rights and uncertainties relating to commercialization rights, as well as those risks, uncertainties and factors referred to in CuraGen's Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by CuraGen from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, CuraGen's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. CuraGen is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



                      (in thousands, except per share data)

                                   Three Months
                                      Ended                Year Ended
                                   December 31,            December 31,
                                   ------------            ------------
                                  2008     2007          2008          2007
                                  ----     ----          ----          ----
                                   (unaudited)              (unaudited)

    Collaboration revenue           $-      $22        $1,174           $88
                                    --      ---        ------           ---

    Operating expenses:
      Research and
       development               2,617    6,299        15,076        36,779
      General and
       administrative              916    2,026         5,151        11,657
      Restructuring charges        529    2,737           529        11,274
                                   ---    -----           ---        ------
        Total operating
         expenses                4,062   11,062        20,756        59,710
                                 -----   ------        ------        ------

      Gain on sale of
       intangible asset              -        -        36,397             -

    (Loss) income from
     operations                 (4,062) (11,040)       16,815       (59,622)
    Interest income                713    1,478         3,356         5,583
    Interest expense              (213)    (995)       (1,687)       (5,167)
    Gain on extinguishment of
     debt                            -    8,273         6,991         8,442
    Realized (loss) gain on
     sale of available-for-
     sale investments, net        (200)    (312)         (372)          616
                                  ----     ----          ----           ---

    (Loss) income from
     continuing operations
     before income taxes        (3,762)  (2,596)       25,103       (50,148)
    Income tax benefit
     (provision)                    40       25          (322)          185
                                    --       --          ----           ---

    (Loss) income from
     continuing operations      (3,722)  (2,571)       24,781       (49,963)
                                ------   ------        ------       -------

    Discontinued operations:
        Loss from
         operations                  -        -             -        (2,991)
        Gain on sale of
         subsidiary                  -        -             -        78,352
    Income from discontinued
     operations                      -        -             -        75,361

    Net (loss) income          ($3,722) ($2,571)      $24,781       $25,398
                               =======  =======       =======       =======

    Basic (loss) income per
     share from continuing
     operations                 ($0.07)  ($0.05)        $0.44        ($0.89)
    Basic income per share
     from discontinued
     operations                      -        -             -          1.35
                                     -        -             -          ----
    Basic net (loss) income
     per share                  ($0.07)  ($0.05)        $0.44         $0.45
                                ======   ======         =====         =====

    Weighted average number
    of shares used in
    computing basic net
    (loss) income
     per share                  56,870   56,279        56,738        55,853
                                ======   ======        ======        ======


                                                  December 31,  December 31,
                                                         2008          2007
                                                         ----          ----

    Cash and investments                              $87,664      $100,444
    Restricted cash                                         -        14,533
                                                            -        ------
        Total cash and
         investments and
         restricted cash                               87,664       114,977
                                                       ======       =======
    Working capital                                    84,044       107,844
                                                       ======       =======
    Total assets                                       88,546       119,282
                                                       ======       =======
    4% Convertible
     subordinated notes
     due 2011                                          18,967        69,890
                                                       ======        ======
    Total long-term
     liabilities                                       18,967        70,975
                                                       ======        ======
    Accumulated deficit                               462,793       487,574
                                                      =======       =======
    Stockholders' equity                               65,465        38,465
                                                       ======        ======

    Sean Cassidy
    Vice President and Chief Financial Officer
    203 871-4400

SOURCE CuraGen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. CuraGen Reports Third Quarter 2008 Financial Results
2. CuraGen Repurchases $50.9 Million of 2011 Convertible Debt for $43.2 Million
3. CuraGen Sells Ownership of Belinostat to TopoTarget A/S
4. CuraGen to Present at the BIO CEO & Investor Conference
5. CuraGen Reports Fourth Quarter and Year End 2007 Financial Results
6. CuraGen Corporation Receives Notification from NASDAQ
7. CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
8. CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
9. CuraGen to Present at the 19th Annual Piper Jaffray Health Care Conference
10. CuraGen Appoints Clinical Oncologist as VP of Medical Development
11. CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... Imagine Exhibitions and Universal Partnerships ... opening in March 2016 at Melbourne Museum in Melbourne, Australia. Immediately following the ... American tour dates. The Exhibition is based on Universal Pictures’ Jurassic World, one ...
(Date:11/30/2015)... , Nov. 30, 2015 Human Longevity, ... the company has acquired Cypher Genomics, Inc., a leading ... human genomic interpretation software solutions. The San ... join HLI including Cypher CEO and Co-founder, Ashley Van ... HLI,s Pediatric Business.  Financial details of the deal were ...
(Date:11/30/2015)... -- HUYA Bioscience International, the leader in accelerating global development ... announced it has signed a Memorandum of Understanding with ... between KDDF and HUYA with the ultimate goal of ... the global market. China,s ... preclinical and clinical stage compounds. The company advances the ...
(Date:11/30/2015)... , Nov. 30, 2015  AbbVie, is introducing ... that focuses on a daily routine for managing the ... their medication can affect the way the body absorbs ... to their a daily routine are important. The goal ... help patients better manage their hypothyroidism by establishing a ...
Breaking Biology Technology:
(Date:11/12/2015)... 2015  Arxspan has entered into an agreement ... for use of its ArxLab cloud-based suite of ... partnership will support the institute,s efforts to electronically ... information internally and with external collaborators. The ArxLab ... the Institute,s electronic laboratory notebook, compound and assay ...
(Date:11/10/2015)...  In this report, the biomarkers market ... type, application, disease indication, and geography. The ... consumables, services, software. The type segments included ... biomarkers, and validation biomarkers. The applications segments ... drug discovery and development, personalized medicine, disease ...
(Date:11/9/2015)... SAN JOSE, Calif. , Nov. 9, 2015 /PRNewswire/ ... of human interface solutions, today announced broader entry into ... of vehicle-specific solutions that match the pace of consumer ... drivers, and biometric sensors are ideal for the automotive ... the vehicle. Europe , ...
Breaking Biology News(10 mins):